haku: @journal_id 44 / yhteensä: 247
viite: 18 / 247
| Tekijä: | Stonebraker, J. S. |
| Otsikko: | How Bayer makes decisions to develop new drugs |
| Lehti: | Interfaces
2002 : NOV-DEC, VOL. 32:6, p. 77-90 |
| Asiasana: | Decision analysis Pharmaceutical industry |
| Vapaa asiasana: | Drugs industry |
| Kieli: | eng |
| Tiivistelmä: | Drug development is time consuming, resource intensive, risky, and heavily regulated. To ensure that it makes the best drug-development decisions, Bayer Pharmaceuticals uses a structured process based on the principles of decision analysis to evaluate the technical feasibility and market potential of its new drugs. DB had analyzed s few had analyzed a few business cases for review by Pharma. |
SCIMA